Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
ST

NASDAQ · STOK

Stoke Therapeutics, Inc.

Healthcare · Biotechnology

$25.32

Down-$0.95 (-3.75%)

Updated Oct 6, 2026, 10:43 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.89B
P/E ratio
47.82
Dividend yield
0.00%
52-week range
$24.21 – $40.22
Volume
928.39K
Avg. volume
1.2M

Price performance · STOK

STOK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

STOK closed at $25.32 after 20 trading sessions, down 15.74% for the selected period.

Last close
$25.32
Period change
-15.74%
Period low
$24.80
Period high
$30.05
Daily close
View OHLC price history
STOK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$25.82$26.31$24.835$25.32928.39K
Oct 2, 2026$26.455$26.455$25.45$25.62848.62K
Oct 1, 2026$26.06$26.51$25.91$26.011.16M
Sep 30, 2026$26.12$26.69$25.88$26.001.87M
Sep 29, 2026$25.305$25.99$25.115$25.881.08M
Sep 28, 2026$24.51$25.71$24.205$25.501.66M
Sep 25, 2026$25.47$25.52$24.80$24.801.22M
Sep 24, 2026$26.09$26.3017$25.00$25.291.22M
Sep 23, 2026$29.22$29.22$26.015$26.111.2M
Sep 22, 2026$28.44$29.40$28.2375$29.20527.22K
Sep 21, 2026$28.80$28.80$27.7475$28.05720.05K
Sep 18, 2026$28.85$28.91$28.01$28.431.56M
Sep 17, 2026$28.41$29.13$28.36$28.93960.06K
Sep 16, 2026$28.25$28.595$27.66$27.91592.03K
Sep 15, 2026$29.56$29.56$27.82$28.151.09M
Sep 14, 2026$29.38$29.70$29.01$29.60500.37K
Sep 11, 2026$29.82$30.16$29.01$29.03587.52K
Sep 10, 2026$29.62$29.785$28.96$29.34421.3K
Sep 9, 2026$29.53$30.53$29.53$29.92666.27K
Sep 8, 2026$29.13$30.68$28.885$30.05680.96K

Latest STOK news

The latest Smart Investors Daily articles mentioning STOK.

Stock researchCompany · Overview

STOK research

Overview

Company profile and research snapshot.

Company profile

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$30.33
Implied upside
—
Analysts
16
STOK recent ratings
DateFirmRatingTarget
Aug 21, 2026JP MorganOverweight—
Aug 4, 2026GuggenheimBuy—
Aug 4, 2026WedbushOutperform—
Aug 4, 2026Canaccord GenuityBuy—
Aug 4, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass., October 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the

Yahoo · Sep 23, 2026

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

BEDFORD, Mass., September 23, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo’s appointment, Edward Kaye, M.D., has retir

Yahoo · Sep 16, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass., September 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By